{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:59:20Z","timestamp":1761487160219},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,5,20]],"date-time":"2004-05-20T00:00:00Z","timestamp":1085011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy and toxicity of factor VIII (FVIII) priming, cyclophosphamide immune suppression, and rapid tapering of concurrent FVIII immune tolerance for subjects with hemophilic inhibitors were evaluated. Four subjects with hemophilic inhibitors were studied. Before treatment, inhibitors were present for a median of 8 months (mean 13 \u00b1 14.0 months). The median FVIII inhibitor titer was 16 BU\/mL (mean 27.2 \u00b1 29.2 BU\/mL). Following FVIII priming (80.0 \u00b1 70.2 U\/kg), subjects received cyclophosphamide 1,418 \u00b1 636 mg\/M<jats:sup>2<\/jats:sup> i.v. q3 weeks for 4.4 \u00b1 1.7 courses. Subjects concurrently received a low (6 U\/kg\/day), moderate (30 U\/kg\/day), or high (100 U\/kg\/day) dose of FVIII followed by a rapid taper as the inhibitor titer decreased or resolved. During treatment, the inhibitor titer initially increased but then rapidly declined. Inhibitors resolved in 3.9 \u00b1 2.9 months. One inhibitor recurred at 2.8 years, but it was successfully re\u2010treated. Effectiveness did not depend on the FVIII dose. Toxicity was minimal. Cyclophosphamide (1,400 mg\/M<jats:sup>2<\/jats:sup>) administered after a priming dose of FVIII (80 U\/kg) i.v. q3 weeks for 2\u20136 cycles with a rapid taper of concurrently administered daily FVIII as the inhibitor titer falls is an effective approach to hemophilic inhibitor ablation. Am. J. Hematol. 76:180\u2013184, 2004. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20066","type":"journal-article","created":{"date-parts":[[2004,5,20]],"date-time":"2004-05-20T22:05:35Z","timestamp":1085090735000},"page":"180-184","source":"Crossref","is-referenced-by-count":7,"title":["Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance"],"prefix":"10.1002","volume":"76","author":[{"given":"Nathan L.","family":"Kobrinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane E.","family":"Sjolander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deb K.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dottie A.","family":"Stegman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V71.2.344.344","article-title":"The natural history of factor VIII inhibitors in patients with hemophilia A. A national cooperative study. II. Observations on the initial development of factor VIII.C inhibitors","volume":"71","author":"McMillan CW","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00032.x"},{"key":"e_1_2_1_4_2","first-page":"213","volume-title":"Hemophilia","author":"Hoyer LW","year":"1997"},{"key":"e_1_2_1_5_2","first-page":"249","volume-title":"Hematology 2000 education program book","author":"Hedner U III","year":"2000"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90871-6"},{"key":"e_1_2_1_7_2","first-page":"180","article-title":"Induced immunotolerance in factor VIII inhibitor patients","volume":"150","author":"Brackmann HH","year":"1986","journal-title":"Progr Clin Biol Res"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80592-2"},{"key":"e_1_2_1_9_2","first-page":"141","article-title":"Treatment of a high titer anti\u2010factor\u2010VIII antibody by continuous factor VIII administration: Report of a case","volume":"58","author":"White GC","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_10_2","first-page":"1949","article-title":"Continuous high\u2010dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated","volume":"58","author":"Scheibel E","year":"1987","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb04122.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1988.03720010043038","article-title":"Induction of immune tolerance of factor VIII in hemophiliacs with inhibitors","volume":"259","author":"Ewing NP","year":"1988","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0038-1661062","article-title":"The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in hemophilia A","volume":"51","author":"Anzar JA","year":"1984","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1975.tb53378.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1660131"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804143181503"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood.V75.2.378.378","article-title":"Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIIII in hemophilia A patients","volume":"75","author":"Nilsson IM","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood.V58.1.38.38","article-title":"A procedure for removing high titre antibodies by extracorporeal protein A Sepharose adsorption in hemophilia: substitution therapy and surgery in patients with hemophilia A and antibodies","volume":"58","author":"Nilsson IM","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_20_2","first-page":"1186","article-title":"Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor FVIII inhibitors: predictors of success","volume":"86","author":"Mariani G","year":"2001","journal-title":"Haemotologica"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00123.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:12:12Z","timestamp":1700154732000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,20]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1002\/ajh.20066"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20066","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,20]]}}}